Atara Biotherapeutics, Inc (ATRA) is a publicly traded Healthcare sector company. As of May 21, 2026, ATRA trades at $9.45 with a market cap of $82.44M and a P/E ratio of 3.63. ATRA moved +0.96% today. Year to date, ATRA is -43.95%; over the trailing twelve months it is +35.00%. Its 52-week range spans $3.92 to $19.15. Analyst consensus is buy with an average price target of $15.50. Rallies surfaces ATRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Atara Biotherapeutics, Inc (ATRA) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. ATRA moved +0.96% today. Analyst consensus is buy.
| Metric | Value |
|---|---|
| Price | $9.45 |
| Market Cap | $82.44M |
| P/E Ratio | 3.63 |
| EPS | $2.61 |
| Dividend Yield | 0.00% |
| 52-Week High | $19.15 |
| 52-Week Low | $3.92 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $120.77M |
| Net Income | $32.69M |
| Gross Margin | 0.00% |
2 analysts cover ATRA: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $15.50.